What is Puma Biotechnology's market cap?

Puma Biotechnology (PBYI) has a market capitalization of $406.7M and trades on NASDAQ.

Who are Puma Biotechnology's competitors?

Puma Biotechnology's key competitors include Merck & Co., Pfizer Inc., Eli Lilly and Company, and others. These companies compete in similar markets and product categories.

Who does Puma Biotechnology partner with?

Puma Biotechnology's notable partners include Pfizer Inc., Takeda Pharmaceutical Company Limited, Pierre Fabre Medicament SAS, and others.

What subsidiaries does Puma Biotechnology have?

Puma Biotechnology's subsidiaries include Puma Biotechnology, Inc. (Private Entity).

Where is Puma Biotechnology headquartered?

Puma Biotechnology is headquartered in United States of America and employs approximately 185 people. It has been publicly traded since 2012.

Puma Biotechnology

PBYI

Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing innovative products to enhance cancer care.

Market cap

$406.69M+159%

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$44.8MBeat by $2.8M EPS-$0.04Beat by $0.09

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$53.0M

EPS estimate$0.04

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Merck & Co.$322.95B+53.0%

Pfizer$140.61B+1.7%

Exelixis$14.0B+15.9%

Zevra Therapeutics, Inc.$574.0M-2.9%

Puma Biotechnology$406.7M+145%

Karyopharm Therapeutics$160.7M+326%

CTO

Citius Oncology, Inc.$51.7M-64.7%

By revenue growth

Zevra Therapeutics, Inc.+201%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

Exelixis35.08%+7.1pp

Eli Lilly34.99%+12.3pp

Pfizer15.65%+6.3pp

Merck & Co.13.59%-13.7pp

Profile

Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing innovative products to enhance cancer care. The company's primary value proposition centers on targeted therapies for HER2-positive breast cancers and other solid tumors. Its lead commercial product is an oral tyrosine kinase inhibitor, and its pipeline includes selective small-molecule inhibitors for various oncology indications.

Competitive position

A commercial-stage biotechnology company with a leading oral therapy for extended adjuvant HER2-positive breast cancer, competing against major global pharmaceutical entities.

GeographiesUnited States, European Union, China, Australia, Canada

Customer segmentsHealthcare Providers, Pharmaceutical Distributors

Business modelProduct-based, Licensing and Royalties

SuppliersThird-party contract manufacturing organizations (CMOs), Contract research organizations (CROs), Active pharmaceutical ingredient (API) suppliers

CustomersSpecialty pharmacies (Accredo, CVS, ONCO 360, Optum, Biologics), Specialty distributors (McKesson, Cardinal Health), Oncology clinics, International sub-licensees

CountryUnited States of America

Listed2012

Employees185.0

CEOAlan H. Auerbach

SectorHealthcare

IndustryBiotechnology

Websitepumabiotechnology.com

FilingsSEC EDGAR

Questions, answered.

What is Puma Biotechnology's market cap?: Puma Biotechnology (PBYI) has a market capitalization of $406.7M and trades on NASDAQ.
Who are Puma Biotechnology's competitors?: Puma Biotechnology's key competitors include Merck & Co., Pfizer Inc., Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
Who does Puma Biotechnology partner with?: Puma Biotechnology's notable partners include Pfizer Inc., Takeda Pharmaceutical Company Limited, Pierre Fabre Medicament SAS, and others.
What subsidiaries does Puma Biotechnology have?: Puma Biotechnology's subsidiaries include Puma Biotechnology, Inc. (Private Entity).
Where is Puma Biotechnology headquartered?: Puma Biotechnology is headquartered in United States of America and employs approximately 185 people. It has been publicly traded since 2012.